The International Congress on CONTROVERSIES IN … 2nd... · by seeking to shed light on ongoing and challenging debates and to bridge ... E. Gluckman , France H ... The International

COSTEM 2nd ann 25/07/2011 15:21 Page 1

Composite

C M Y CM MY CY CMY K

THE ACADEMY FOR CLINICAL DEBATES & CONTROVERSIES IN MEDICINE

BERLIN • GERMANY • SEPTEMBER 8-11, 2011

Last update: July 25, 2011

CONTROVERSIES INSTEM CELL TRANSPLANTATION

AND CELLULAR THERAPIES

The International Congress on

www.comtecmed.com/costem | [email protected] comprehensive Congress fully devoted to clinical debates and controversial issues in the fields of Stem Cell Transplantation and Cellular Therapies

2nd ANNOUNCEMENT2nd ANNOUNCEMENT


Composite


The International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM)Berlin, Germany • September 8-11, 2011

Over the years, the fields of Stem Cell Transplantation and Cellular Therapies haveundergone enormous expansion in clinical trials and basic research as well as in cutting-

edge technology.The International Congress on Controversies in Stem Cell Transplantation and

Cellular Therapies (COSTEM) will function as an exclusive forum for internationalexperts to share and compare experiences, in order to outline the right treatment for

patients. This innovative Congress is unique in its explicit focus on resolving controversiesin best clinical care of patients.

Academically, the Congress will raise the most dynamic and controversial topics facingclinicians in an exciting and engaging debate forum. The Congress will promote excellenceby seeking to shed light on ongoing and challenging debates and to bridge gaps between

the expansion of information and its consolidation in clinical practice.Participants will have the advantage of discussing and debating these unresolved issues

with leading world experts in all fields of Stem Cell Transplantation and CellularTherapies. Allowing ample time for speaker-audience discussion, the Congress aims atreaching up-to-date and agreed-upon answers to ongoing debates even when proof is

lacking, through evidence-based medicine and expert opinion.We invite you to take part in the COSTEM Congress which is intended as the inaugural

event of future editions.We look forward to an exciting event in the beautiful city of Berlin.

Prof. N. Kröger and Prof. A. NaglerCo-Chairpersons

On behalf of the Organizing Committee

Dear Friends and Colleagues,


Composite



FACULTY(Preliminary list)

J.F. Apperley, UKW. Arcese, ItalyR. Arnold, GermanyA. Bacigalupo, ItalyP. Bader, GermanyB. Barlogie, USAJ. Blade, SpainD. Blaise, FranceP. Borchmann, GermanyM. Bornhäuser, GermanyC. Brunstein, USAM. Cavazzana-Calvo, FranceF. Ciceri, ItalyP. Corradini, ItalyM. de Lima, USAH.J. Deeg, USAV. Diehl, GermanyU. Dührsen, GermanyG. Ehninger, GermanyH. Einsele, GermanyJ.H.F. Falkenburg, The NetherlandsD. Farge-Bancel, France

J.L. Ferrara, USAJ. Finke, GermanyG. Gahrton, SwedenS.A. Giralt, USAC. Gisselbrecht, FranceE. Gluckman, FranceH. Goldschmidt, GermanyH. Greinix, AustriaR. Handgretinger, GermanyJ.L. Harousseau, FranceR. Hehlmann, GermanyD. Hoelzer, GermanyH. Hof, GermanyE. Holler, GermanyH.J. Kolb, GermanyK. Le Blanc, SwedenP. Ljungman, SwedenF. Locatelli, ItalyS. Mackinnon, UKA. Madrigal, UKM.F. Martelli, ItalyG. Maschmeyer, Germany

R.A. Mesa, USAJ. Miller, USAM. Mohty, FranceD. Niederwieser, GermanyE. Olavarria, SpainJ.R. Passweg, SwitzerlandC. Peters, AustriaP. Reimer, GermanyY. Reisner, IsraelS. Riddell, USAV. Rocha, FranceJ.M. Rowe, IsraelG. Sanz, SpainA. Shimoni, IsraelJ. Sierra, SpainS. Slavin, IsraelG. Socié, FranceP. Sonneveld, The NetherlandsR. Storb, USAA. Sureda, UKL. Uharek, GermanyA.R. Zander, Germany

Renate ArnoldGermany

Lutz UharekGermany

LOCAL ORGANIZING COMMITTEE

Jürgen FinkeGermany

Alejandro MadrigalUK

Dietger NiederwieserGermany

Jacob M. RoweIsrael

ORGANIZING COMMITTEE

Nicolaus KrögerGermany

Arnon NaglerIsrael

CO-CHAIRPERSONS

[ 3 ]


Composite



PRELIMINARYSCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 9, 2011

HALL A

14:00-15:30 SESSION 4: TREATMENT ANDPREVENTION OF RELAPSE

SECOND ALLO FOR RELAPSEChair: J. Miller, USA

14:00-14:15 Yes: S. Slavin, Israel14:15-14:30 No: To be announced14:30-14:45 Discussion

DONOR SELECTION TO PREVENTRELAPSEChair: M. de Lima, USA

14:45-15:00 According to KIR typing: J. Miller, USA15:00-15:15 According to HLA typing:

A. Madrigal, UK15:15-15:30 Discussion

15:30-16:00 Coffee Break

16:00-17:30 SESSION 6: REFRACTORY ANDRESIDUAL LEUKEMIA

ALLO SCT FOR REFRACTORYLEUKEMIAChair: J.M. Rowe, Israel

16:00-16:15 Yes: M. Mohty, France16:15-16:30 No: D. Blaise, France16:30-16:45 Discussion

SHOULD ALL MRD POSITIVEPATIENTS RECEIVE ALLO SCT?Chair: C. Peters, Austria

16:45-17:00 Yes: P. Bader, Germany17:00-17:15 No:To be announced17:15-17:30 Discussion

08:30-10:00 PLENARY SESSION 1:SCT IN MYELOMA AND MDSChairs: N. Kröger, Germany &A. Nagler, Israel

08:30-08:35 Co-Chairpersons Introduction

AUTOLOGOUS SCT AS FIRST LINETREATMENT?

08:35-08:45 Yes: J.L. Harousseau, France08:45-08:55 No: J. Blade, Spain08:55-09:15 Discussion

ALLO SCT IN ELDERLY PATIENTS(>60 Y) WITH MDS

09:15-09:30 Yes: N. Kröger, Germany09:30-09:45 No: H.J. Deeg, USA09:45-10:00 Discussion


10:30-12:00 SESSION 2:RELAPSE PREVENTION

RELAPSE PREVENTION:PROPHYLACTIC DLI?Chair: A.R. Zander, Germany

10:30-10:45 Yes: H.J. Kolb, Germany10:45-11:00 No: A. Bacigalupo, Italy11:00-11:15 Discussion

CAN WE PREVENT RELAPSE BYNOVEL CONDITIONING REGIMEN?Chair: S.A. Giralt, USA

11:15-11:30 Yes: M. de Lima, USA11:30-11:45 No: A. Shimoni, Israel11:45-12:00 Discussion

12:00-13:00 Lunch

13:00-14:00 To be announced

[ 4 ]

HALL B

10:30-12:00 SESSION 3: AML AND CML

INDICATION FOR UNRELATED ALLOSCT IN 1. CR AMLChair: M. Mohty, France

10:30-10:45 Yes: D. Niederwieser, Germany10:45-11:00 No: J. Sierra, Spain11:00-11:15 Discussion

ALLOGENEIC SCT FOR CML AFTERFAILURE TO 1. TKIChair: R. Hehlmann, Germany

11:15-11:30 Yes: E. Olavarria, Spain11:30-11:45 No: J.F. Apperley, UK11:45-12:00 Discussion

12:00-13:00 Lunch

14:00-15:30 SESSION 5: APLASTIC ANEMIA ANDAUTOIMMUNE DISEASES

MUD OR IMMUNSUPPRESSIVETHERAPY FOR APLASTIC ANEMIAChair: J. Finke, Germany

14:00-14:15 MUD: J.R. Passweg, Switzerland14:15-14:30 IS: To be announced14:30-14:45 Discussion

AUTOLOGOUS SCT FOR AUTOIMMUNEDISEASEChair: R. Arnold, Germany

14:45-15:00 Yes: D. Farge-Bancel, France15:00-15:15 No: To be announced15:15-15:30 Discussion



Composite



[ 5 ]

FRIDAY, SEPTEMBER 9, 2011

HALL B


SATURDAY, SEPTEMBER 10, 2011HALL A

16:00-17:30 SESSION 7: GvHD PREVENTION BYT-CELL MODULATION

CAN TREG PREVENT GvHD WITHOUTLOOSING GvL?Chair: E. Holler, Germany

16:00-16:15 Yes: M.F. Martelli, Italy16:15-16:30 No: J.L. Ferrara, USA16:30-16:45 Discussion

16:00-17:30 SESSION 7 (continued)

IS PHOTOPHERESIS TREATMENT OFCHOICE FOR cGvHD?Chair: H.J. Deeg, USA

16:45-17:00 Yes: H. Greinix, Austria17:00-17:15 No: G. Socié, France17:15-17:30 Discussion

8:30-10:00 SESSION 8: CORD BLOOD

IS DOUBLE CORD BLOOD TO BEPREFERRED TO A SINGLE UNIT?Chair: E. Gluckman, France

08:30-08:45 Yes: C. Brunstein, USA08:45-09:00 No: G. Sanz, Spain09:00-09:15 Discussion

SHOULD CORD BLOOD UNIT BESELECTED ACCORDING TO HLA ORCELL-BASED?Chair: V. Rocha, France

09:15-09:30 Cell-based: E. Gluckman, France09:30-09:45 HLA-based: C. Brunstein, USA09:45-10:00 Discussion


10:30-12:00 SESSION 10: DONOR SELECTION

WHICH IS THE DONOR OF CHOICE IFNO MUD IS AVAILABLE?Chair: A. Madrigal, UK

10:30-10:45 Haplo: L. Uharek, Germany10:45-11:00 Cord blood: W. Arcese, Italy11:00-11:15 Discussion

SHOULD WE EXPAND CORD BLOOD?Chair: W. Arcese, Italy

11:15-11:30 Yes: G. Sanz, Spain11:30-11:45 No: V. Rocha, France11:45-12:00 Discussion

12:00-12:45 Lunch

12:45-14:00 NOVARTIS SATELLITE SYMPOSIUM

14:00-15:30 SESSION 12: LYMPHOMA

AUTOLOGOUS SCT IN FLChair: A. Sureda, UK

14:00-14:15 Yes: C. Gisselbrecht, France14:15-14:30 No: U. Dührsen, Germany14:30-14:45 Discussion

TRANSPLANTATION FOR T-CELLLYMPHOMAChair: C. Gisselbrecht, France

14:45-15:00 Pro auto: P. Reimer, Germany15:00-15:15 Pro allo: P. Corradini, Italy15:15-15:30 Discussion


16:00-17:30 SESSION 14: ALLOGENEIC SCT FORMYELOMA AND HODGKIN'S DISEASE

IS THERE A PLACE FOR ALLO SCT INTREATMENT OF MM?Chair: N. Kröger, Germany

16:00-16:15 Yes: G. Gahrton, Sweden16:15-16:30 No: H. Goldschmidt, Germany16:30-16:45 Discussion

IS THERE A PLACE FOR ALLO SCT INHODGKIN’S DISEASE?Chair: V. Diehl, Germany

16:45-17:00 Yes: A. Sureda, UK17:00-17:15 No: P. Borchmann, Germany17:15-17:30 Discussion


Composite



SATURDAY, SEPTEMBER 10, 2011HALL B

14:00-15:30 SESSION 13: T-CELL DEPLETION ANDMESENCHYMAL STROMA CELLS

T-CELL DEPLETION AND T-CELLADD BACKChair: L. Uharek, Germany

14:00-14:15 Yes: J.H.F. Falkenburg, The Netherlands14:15-14:30 No: R. Storb, USA14:30-14:45 Discussion

MSC FOR GvHDChair: M. Bornhäuser, Germany

14:45-15:00 Yes: K. Le Blanc, Sweden15:00-15:15 No: F. Locatelli, Italy15:15-15:30 Discussion


16:00-17:30 SESSION 15: GvHD PREVENTION BYANTIBODIES

GvHD PREVENTIONChair: A.R. Zander, Germany

16:00-16:15 Pro ATG: J. Finke, Germany16:15-16:30 Pro Alemtuzemab: S. Mackinnon, UK16:30-16:45 Discussion

IS IT POSSIBLE TO SEPARATE GvHDFROM GvL?Chair: J.L. Ferrara, USA

16:45-17:00 Yes: E. Holler, Germany17:00-17:15 No: H.J. Deeg, USA17:15-17:30 Discussion

[ 6 ]


08:30-10:00 SESSION 16: IMPROVINGTRANSPLANT OUTCOME IN MULTIPLEMYELOMA

SHOULD CR BE TARGET OF THERAPYIN MM?Chair: J.L. Harousseau, France

08:30-08:45 Yes: S.A. Giralt, USA08:45-09:00 No: B. Barlogie, USA09:00-09:15 Discussion

8:30-10:00 SESSION 9: MYELOFIBROSIS ANDHAPLOIDENTICALTRANSPLANTATION

ALLO SCT FOR ELDERLYMYELOFIBROSIS PATIENTS (> 60 Y)Chair: A. Bacigalupo, Italy

08:30-08:45 Yes: N. Kröger, Germany08:45-09:00 No: R.A. Mesa, USA09:00-09:15 Discussion

SHOULD HAPLO-SCT BE PERFORMEDWITH T-CELL DEPLETION?Chair: Y. Reisner, Israel

09:15-09:30 Yes: R. Handgretinger, Germany09:30-09:45 No: F. Ciceri, Italy09:45-10:00 Discussion


10:30-12:00 SESSION 11: CELLAND GENE THERAPY

IS SPECIFIC T-CELL THERAPYTARGETING mHag USEFUL?Chair: F. Locatelli, Italy

10:30-10:45 Yes: S. Riddell, USA10:45-11:00 No: M. Bornhäuser, Germany11:00-11:15 Discussion

GENE THERAPY FOR GENETICDISEASES (SCID, FA, CGD)Chair: R. Handgretinger, Germany

11:15-11:30 Yes: M. Cavazzana-Calvo, France11:30-11:45 No: To be announced11:45-12:00 Discussion

12:00-12:45 Lunch

SUNDAY, SEPTEMBER 11, 2011

HALL A


THERAPY POST TRANSPLANTATIONIN MMChair: B. Barlogie, USA

09:15-09:30 Pro consolidation: J. Blade, France09:30-09:45 Pro maintenance:

P. Sonneveld, The Netherlands09:45-10:00 Discussion


Composite



[ 7 ]


SUNDAY, SEPTEMBER 11, 2011

HALL A


IS COMBINED ANTIFUNGALTHERAPY MORE EFFICIENT THANSINGLE AGENT THERAPY?Chair: H. Einsele, Germany

09:15-09:30 Yes: To be announced09:30-09:45 No: G. Maschmeyer, Germany09:45-10:00 Discussion

08:30-10:00 SESSION 17: INFECTION

SHOULD CMV INFECTION POSTALLO SCT BE TREATED BY CELL-BASED THERAPY?Chair: S. Riddell, USA

08:30-08:45 Yes: H. Einsele, Germany08:45-09:00 No: P. Ljungman, Sweden09:00-09:15 Discussion

HALL B

SPONSORS

GOLD

SILVER

SPONSORS

PLATINUM

10:00-11:00 PLENARY SESSION 18:FUNGAL RESISTANCESupported by an unrestricted grantfrom Gilead

ASPERGILLUS RESISTANCE IS ONLYSEEN ON THE PETRI DISH AND NOTIN THE PATIENT

10:00-10:05 Chair: N. Kröger, Germany10:05-10:25 Pro: H. Hof, Germany10:25-10:45 Con: G. Maschmeyer, Germany10:45-11:00 Discussion


11:30-13:00 PLENARY SESSION 19:ALL AND INTENSITY OFCONDITIONING REGIMEN

IS THERE A ROLE FOR ALLO SCT INSTANDARD RISK ALL?Chair: D. Niederwieser, Germany

11:30-11:45 Yes: J.M. Rowe, Israel11:45-12:00 No: D. Hoelzer, Germany12:00-12:15 Discussion

REDUCED OR STANDARDCONDITIONING?Chair: G. Ehninger, Germany

12:15-12:30 Pro reduced: R. Storb, USA12:30-12:45 Pro standard: A. Nagler, Israel12:45-13:00 Discussion


Composite



DATES: September 8-11, 2011

VENUE: Andel’s Hotel Berlin, GermanyLandsberger Allee 106 D-10369 Berlin, DeutschlandTel: +49-30-453-053-2325, Fax: +49-30-453-053-2299www.andelsberlin.com

ACCOMMODATIONComtecMed is the official travel agent for the International Congress on Controversies in Stem CellTransplantation and Cellular Therapies (COSTEM) and will offer special reduced rates for accommodation.

Rates shown are per room, per night and include buffet breakfast and taxes.Additional hotels in different categories are available upon request.* Accesses to the executive floor lounge, all room are equipped with bathrobe and slippers, international newspapers,internet access free of charge.

LIABILITY AND INSURANCEThe Congress Secretariat and Organizers will not accept liability for personal accidents, nor loss of ordamage to private property of participants, either during or directly arising from the International Congresson Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM). Participants shouldmake their own arrangements with respect to health and travel insurance.

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed materialof the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

Early Registration Late Registration FromUntil July 13 – September 1, 2011

July 12, 2011 August 31, 2011 and On Site

Participants -Physicians and Scientists Є490 Є540 Є590

Residents, Nurses, Students Є365 Є410 Є450

GENERAL INFORMATION

REGISTRATION FEES

Headquarters and Administration:53 Rothschild Boulevard,PO Box 68,Tel Aviv 61000, IsraelTel: +972-3-5666166Fax: +972-3-5666177Email: [email protected]

www.comtecmed.com/[email protected]

Comtec China:175 Xiang Yang Road South,Shanghai 200031ChinaTel: +86-21-54660460Fax: +86-21-54660450Email: [email protected]

Comtec Spain:Bailén, 95-97,pral. 1. a - 08009Barcelona, SpainTel: +34-93-2081145Fax: +34-93-4579291Email: [email protected]

Andel's Hotel BerlinCongress Venue

Type of Room Single Room Double Room

Superior Room Є128 Є148

Deluxe Room Є148 Є168

Executive Floor* Є158 Є178

Documents

The International Congress on CONTROVERSIES IN … 2nd... · by seeking to shed light on ongoing and challenging debates and to bridge ... E. Gluckman , France H ... The International